The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease by Liu, Yang et al.
The Role of Phospholipase D in Modulating the MTOR
Signaling Pathway in Polycystic Kidney Disease
Yang Liu1, Andres Käch2, Urs Ziegler2, Albert C. M. Ong3, Darren P. Wallace4, Alexandre Arcaro5, Andreas
L. Serra1*
1 Institute of Physiology, University of Zurich, Zürich, Switzerland, 2 Center for Microscopy and Image Analysis, University of Zurich, Zürich, Switzerland,
3 Academic Unit of Nephrology, Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 4 Department of Medicine, University
of Kansas Medical Center, Kansas City, Kansas, United States of America, 5 Department of Clinical Research, University of Bern, Bern, Switzerland
Abstract
The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in polycystic kidney disease
(PKD). Emerging evidence suggests that phospholipase D (PLD) and its product phosphatidic acid (PA) regulate
mTOR activity. In this study, we assessed in vitro the regulatory function of PLD and PA on the mTOR signaling
pathway in PKD. We found that the basal level of PLD activity was elevated in PKD cells. Targeting PLD by small
molecule inhibitors reduced cell proliferation and blocked mTOR signaling, whereas exogenous PA stimulated mTOR
signaling and abolished the inhibitory effect of PLD on PKD cell proliferation. We also show that blocking PLD activity
enhanced the sensitivity of PKD cells to rapamycin and that combining PLD inhibitors and rapamycin synergistically
inhibited PKD cell proliferation. Furthermore, we demonstrate that targeting mTOR did not induce autophagy,
whereas targeting PLD induced autophagosome formation. Taken together, our findings suggest that deregulated
mTOR pathway activation is mediated partly by increased PLD signaling in PKD cells. Targeting PLD isoforms with
pharmacological inhibitors may represent a new therapeutic strategy in PKD.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is a
inherited kidney disease characterized by progressive
development of fluid-filled cysts in both kidneys, which results
in end-stage renal disease in approximately 50% of affected
individuals by the sixth decade of life. ADPKD is caused by
mutations in the PKD1 (approximately 85%) and PKD2
(approximately 15%) genes encoding polycystin-1 and 2 (PC1
and PC2). PC1 and PC2 function in cell-cell and cell-matrix
interactions, signal transduction and mechanosensation [1,2]. A
direct physical interaction exists between the cytoplasmic tail of
PC1 and the tumor suppressor tuberin, the product of the
TSC2 gene that regulates the kinase activity of mTOR.
Mutations in PC1 disrupt this interaction, unleashing mTOR
and in turn, promote the proliferation of cyst-lining epithelial
cells in ADPKD by aberrant signaling through mTOR [3]. .
mTOR is a Ser/Thr kinase that governs a wide variety of
biological and cellular processes, including cell growth,
proliferation, survival and autophagy [4,5]. mTOR is composed
of two functionally and structurally distinct complexes:
mTORC1 and mTORC2 [6]. The binding of raptor to mTOR
defines the nutrient-sensitive mTORC1 that regulates protein
synthesis by phosphorylating its substrates the 4E-binding
protein1 (4E-BP1) and the 70-kD ribosomal S6 kinases (S6K)
[7]. Rapamycin in a complex with its intracellular receptor
FKBP12 specifically binds to the FKBP12/rapamycin binding
domain of mTOR and inhibits mTORC1 function. mTORC2,
assembled by the binding of rictor, a rapamycin-insensitive
companion of mTOR, is activated by growth factors alone. The
commonly described substrate of mTORC2 is Akt at the
Ser473 site [8].
Phosphatidic acid (PA), a phospholipase D (PLD) product
generated by the hydrolysis of phosphatidylcholine, regulates
mTOR activity [9]. PLD is activated by a variety of hormones,
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growth factors and cytokines. Two PLD isoforms are expressed
in most mammalian tissues: PLD1 and PLD2, which are
endowed with different properties, regulatory mechanisms and
functions [10]. PA is required for the stability of mTORC1 and
mTORC2 and modulates the kinase activity of both complexes.
PA interacts with mTOR in a manner that is competitive with
rapamycin. As a consequence, elevated PLD activity confers
rapamycin resistance [11]. Aberrant PLD/PA signaling has
been observed in a number of human carcinomas, including
breast, ovary, kidney and colon cancer [12–14]. The elevated
PLD activity in human carcinomas is thought to promote cell
proliferation and to suppress the default apoptotic programs,
thereby promoting cancer growth. We hypothesized that PLD
activity governs PKD associated cell proliferation via the mTOR
signaling pathway in PKD; however this has not been
examined yet.
Autophagy, also called “self-eating”, is an evolutionarily
conserved cellular pathway whereby cytosolic components are
targeted for removal into membrane-bound compartments,
named autophagosomes [15]. Autophagy has been well
established as a cytoprotective mechanism under stress
conditions, such as starvation. A number of studies have
provided evidence that inadequate levels of autophagy can
also lead to non-apoptotic cell death [15,16]. As mTOR
signaling modulates autophagy and abnormally increased
mTOR signaling is a feature of PKD, a connection between
autophagy and PKD has been proposed [17]. However, there is
so far only one report showing abnormalities in autophagy and
autophagy-related proteins in PKD animal models [18].
In the current study, we show for the first time that PLD
activity is abnormally elevated, and partly contributes to mTOR
pathway activation in PKD cells. The mTOR signaling pathway
is modulated in a PLD-dependent way in PKD. Inhibition of
PLD activity increased the inhibitory effect of rapamycin on
mTOR. Furthermore, targeting PLD impaired cell proliferation
and induced autophagy, which may represent an opportunity
for the development of new treatment strategies for PKD [19].
Materials and Methods
Antibodies and reagents
All commercial antibodies and chemicals were purchased
from the following suppliers: anti-phospho-(T308)-Akt (4056),
anti-phospho-(S473)-Akt (4051), anti-phospho-(T389)-p70 S6K
(9206), anti-phospho-(T421/S424)-p70 S6K (9204), anti-p70
S6K (2708), anti-LC3B (3868), anti-caspase 3 (9662), anti-
phospho-(S561)-PLD1(3834), anti-PLD1(3832), anti-phospho-
(S235/236)-S6 (2211), anti-S6, anti-phospho-(T37/46)-4EBP1
(9459), anti-4EBP1(9644), anti-phospho-(S2448)-mTOR
(2971), anti-mTOR (2983), anti-Atg5 (8540) antibodies were
from Cell Signaling Technology; anti-Akt (ab8805-200) was
from Abcam; anti-GAPDH (MAB374) was from Merck Millipore;
anti-phospho-(Y169)-PLD2 (A8400) was from Assay Biotech;
anti-PLD2 (sc18532) was from Santa Cruz; Sheep anti-mouse
IgG-HRP (NA931A) and donkey anti-rabbit IgG-HRP (NA934A)
were from GE Healthcare; Alexa Fluor 488 donkey anti-rabbit
IgG (A21206) was from Life technology; 1,2-dioleoyl-sn-
glycero-3-phosphoric acid monosodium salt (DOPA, 74304),
rapamycin (R0395), honokiol (H4914), 1-BtOH (B7906) and
tert-BtOH (19460) were from Sigma-Aldrich AG. PLD1 and
PLD2 inhibitors were kindly provided from Prof. H. Alex Brown
and Prof. Craig W. Lindsley.
Primary and immortalized renal tubular epithelial cell
cultures
The Han: SPRD rat colony was established in our animal
facility from a litter which was obtained from the Rat Resource
& Research Center (Columbia, MO, USA) and kept under local
regulation and guidelines. The animal study was approved by
the animal health regulatory agency of the Canton Zürich,
Switzerland. Heterozygous cystic (Cy/+) and wild-type normal
(+/+) male rats, aged 8-weeks-old were used in this study.
Primary renal epithelial cells were isolated as follows: kidneys
were minced and digested by 1 mg/ml collagenase with gentle
agitation for 1 hour at 37°C. The suspension was allowed to
sediment for 1 minute twice. Cells were collected by harvesting
the supernatant and then washed 3 times with 10% FBS/
HBSS. Isolated cells were re-suspended in K1 medium (1:1
mixture of Dulbecco’s modified Eagle’s medium and Ham’s
F-12 medium supplemented with 5% FBS,10 mM HEPES, 42
mM sodium bicarbonate, 50 ng/ml insulin, 50 nM
hydrocortisone, 50 ng/ml transferrin, 5 pM trijodothyronine, 100
IU/ml penicillin, and 100 µg/ml streptomycin). Cells were
seeded in collagen type 1-precoated culture dishes.
Primary cultures of normal human kidney epithelial cells
(NHK) and ADPKD cyst-lining renal epithelial cells (ADPKD)
were generated by the PKD Research Biomaterials and
Cellular Models Core at the University of Kansas Medical
Center (Kansas City, KS, USA) [20]. Human immortalized
cystic (OX161) and noncystic (UCL93) cells were kindly
provided by Prof. A.C. Ong (University of Sheffield, Sheffield,
UK) [21]. The culture conditions of human primary and
immortalized renal epithelial cells were the same as for rat
primary renal tubular epithelial cells.
Cell viability and proliferation assays
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS)-based CellTiter 96 AQueous One assay (G3581,
Promega) was used to quantify cell viability. Cell proliferation
was assessed using BrdU Cell Proliferation ELISA Kit
(11647229001, Roche Applied Science), which quantifies cell
proliferation by measuring DNA synthesis. The assay was
performed according to the manufacturer’s instructions and
results were expressed as mean absorbance of the samples
measured in an ELISA plate reader.
Western blot analysis
Total cell lysates were prepared in the ice-cold lysis buffer
containing 40 mM Hepes, 120 mM NaCl, 1 mM EDTA and 1%
Triton (pH 7.5), supplemented with proteinase inhibitors
(Roche) and phosphatase inhibitors (10 mM potassium
pyrophosphate, 10 mM sodium β-glycerophosphate, 50 mM
sodium fluoride, 0.5 mM sodium orthovanadate). The amount
of protein was determined by using the BCA Protein Assay
(23225, Thermo Scientific). Cell lysates in SDS-sample buffer
Phospholipase D and Polycystic Kidney Disease
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were boiled for 10 minutes at 95ºC and equal protein amounts
were resolved by SDS-PAGE, immunoblotted using
polyvinylidene difluoride membranes and probed with
antibodies. Signals were visualized by using the Chemiglow
West chemiluminescence substrate kit (60-12596-00,
ProteinSimple).
Preparation of PA
DOPA (74304, Sigma-Aldrich AG) was dissolved in
chloroform and dried under nitrogen. The lipid film was
resuspended in vesicle buffer (150 mM NaCl and 10 mM Tris-
Cl (pH8.0)) by vortexing briefly to yield a final lipid
concentration of 10 mM. The lipid suspension was then
sonicated in a water bath sonicator for 5 min. This procedure is
expected to yield small unilamellar vesicles with diameters in
the range of 15-50 nm. Lipid vesicles were made freshly before
each experiment and were added directly to cell medium at the
final concentration of 100 µM. Due to the short half-life of PA,
this process was repeated every 40 min throughout treatment.
PLD enzyme activity
The protein samples were collected and the concentration
determined using the same procedures as describes for the
Western blot assay. 50 µg of protein samples were used to
determine PLD activity with the Amplex Red PLD assay kit
(A12219, Invitrogen), according to the manufacturer’s protocol.
Immunofluorescence staining
Cells were seeded into 6-well plates with coverslips. 24 h
later, cells were treated with or without PLD inhibitors for 48 h.
Cells grown on the coverslips were fixed and permeabilized
with ice-cold methanol at -20°C for 10 min. After 3 washes with
PBS, the samples were blocked with blocking buffer (1% BSA,
1% Triton X-100 in PBS (pH 7.4)) at room temperature for 30
min. The samples were then incubated with primary antibody
(anti-LC3B) at room temperature for 2 h. After 3 washes with
PBS, the samples were incubated with Alexa Fluor 488 donkey
anti-rabbit IgG at room temperature avoiding light for 1 h.
Slides were examined by using a laser scanning confocal
microscope (Leica SP5).
Transmission electron microscopy
ADPKD and OX161 cells treated with or without either 10 µM
PLD1 inhibitor or 20 µM PLD2 inhibitor for 48 h were fixed for 2
h at room temperature (RT) with 2.5% glutaraldehyde in PBS
(pH 7.4) and, subsequently, with 1% OsO4 in 50 mM sodium
cacodylate buffer (pH 7.3), dehydrated in an ethanol series and
embedded into epon (Catalyst). Ultrathin sections of 50 nm
were contrasted with uranyl acetate and lead citrate and
analyzed in a Tecnai Spirit transmission electron microscope
(FEI) with an ORIUS CCD camera (Gatan).
Statistical analyses
Statistical analyses were performed by one-way ANOVA with
the Dunnet post-hoc test. All data are expressed as means ±
SD. P values were two sided for the comparison between the
groups or between baseline and follow-up values, and those
less than 0.05 were considered statistically significant.
Results
Elevated mTOR and PLD activity in PKD cells
In this study, we used 3 different PKD cellular models: 1)
primary renal tubular epithelial cells derived from heterozygous
Cy/+ and +/+ Han: SPRD rats, a well characterized strain
(Cy/+), which phenotypically resembles human ADPKD [22]; 2)
an immortalized human ADPKD renal tubular epithelial cell line
(OX161) and an immortalized normal renal tubular epithelial
cell line (UCL93) [21]; and 3) primary renal epithelial cells
derived from ADPKD patients (ADPKD) and from normal
human kidney tissue (NHK) [23]. Western blots analysis was
used to examine the expression of regulators and effectors of
mTOR complexes in the PKD renal cystic epithelial cells, and
were compared with normal renal tubular epithelial cells. Figure
1A shows the markers of activation of mTORC1
(phosphorylation at T308 of Akt, and at T389 of S6K) and
mTORC2 signaling pathway (phosphorylation at S473 of Akt).
Mutations in PKD1 or PKD2 lead to profound effects on
downstream target tuberous sclerosis complex (TSC)-mTOR
pathway in ADPKD. In our study, the basal activity of mTOR,
assessed by the phosphorylation status of the mTOR readouts
Akt and S6K, was higher in the primary PKD cells, compared
with normal renal epithelial cells. In the immortalized cells, we
observed that both OX161 and UCL93 cells had high activation
of Akt and S6K, which suggests that the elevated mTOR
pathway activity is associated with increased cell proliferation
in immortalized PKD and normal cells.
Since it was recently shown that aberrant PLD activity is
associated with several human cancers, and PA, a product of
PLD activation, is required for the stability and activity of the
mTOR complex, we hypothesized that the abnormal mTOR
pathway activation could be partly due to high basal PLD
activity in PKD. To test this hypothesis, we examined
endogenous PLD activity by measuring its activity in vitro. In
this study, we used honokiol to treat OX161 as a positive
control when measuring PLD activity with the specific
enzymatic assay [24]. Honokiol, a bioactive compound
obtained from several species of the genus Magnolia of
Magnoliaceae family, suppressed the PLD activity through
targeting the activation of the upstream regulator Ras [25]. The
data presented in Figure 1B shows that the basal level of PLD
activity is increased in all investigated PKD cell models
compared with normal renal epithelial cells and that honokiol
decreased PLD activity of OX161 cells.
PLD Inhibitors Impair Cell Proliferation in Renal Tubular
Epithelial Cells
Since up-regulated PLD activity was observed in all PKD
cells we hypothesized that targeting PLD could be an effective
treatment strategy for PKD. We therefore examined the
efficacy of specific inhibitors of PLD1 and PLD2 on PKD cell
proliferation which was determined by MTS, BrdU and cell
counting assays [26]. The PLD inhibitors we used as Scott SA
et al. reported that directly interact with the catalytic domains of
Phospholipase D and Polycystic Kidney Disease
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the enzyme, and do not require binding with the regulatory PX-
PH domain to execute inhibition [26]. Figure 2 shows that both
PLD1 and 2 inhibitors reduced cell viability, DNA synthesis and
cell proliferation in normal and PKD cells in a dose-dependent
way. Both PLD inhibitors proved cytotoxic in all cell types and
the PLD1 inhibitor exhibited a higher efficacy in reducing cell
proliferation compared with the PLD2 inhibitor.
PLD inhibitors specific target PLD
We next focused our study on human PKD cells to examine
whether PLD inhibitors could specifically block PLD
phosphorylation. Western blot analysis indicated that the dose-
dependent effect of PLD inhibitors with the reduced
phosphorylation levels of PLD1 and PLD2. Figure 3A shows
that both PLD1 and PLD2 inhibitors reduced specifically the
phosphorylation of PLD1 and PLD2, respectively. Using an
enzymatic assay to correlate the inhibition of phosphorylation
with PLD activity we found that both PLD inhibitors reduced
total PLD activity in ADPKD and OX161 cell lysates (Figure
3B). Inhibition of PLD activity was dose-dependent and
maximal at doses of 10 µM and 20 µM for the PLD1 and PLD2
inhibitor, respectively.
Figure 1.  Elevated mTOR and PLD activity in PKD
cells.  (A) Western blots and densitometry analyzing the
endogenous activity of the mTOR in PKD and control cells. (B)
The endogenous level of PLD activity was determined in PKD
and control cells by the Amplex Red PLD assay kit. Honokiol
(20 µM) treated OX161 for 20 h as a positive control. An
experiment which is representative of three independent
experiments is shown. Data are expressed as mean ± SD and
were analyzed by one-way ANOVA. * p< 0.05, ** p< 0.01, ***
p< 0.001.
doi: 10.1371/journal.pone.0073173.g001
PLD inhibitors affect the mTOR signaling pathway,
while exogenous PA stimulates mTOR signaling
PA is known to mediate the activation of mTOR signaling by
binding to the FKBP12-rapamycin binding (FRB) domain of
mTOR. Since we found that the activity of PLD was elevated in
PKD, we tested the hypothesis that PLD activity is required to
sustain the activation the mTOR signaling pathway in human
PKD cells. Thus we treated ADPKD and OX161 cells with
PLD1 and PLD2 inhibitors and examined their effect on the
phosphorylation of the up- and down-stream targets of the
mTOR pathway. We found that the phosphorylation of both the
up-stream targets of mTORC1 (phospho-T308-Akt) and the
down-stream targets (phospho-T421/S424-S6K, phospho-
S235/236 S6, phospho-T37/46-4E-BP1) decreased in a dose-
dependent manner (Figure 4A). The readout for mTORC2,
phospho-S473-Akt, also decreased upon PLD1 and PLD2
inhibitor treatment (Figure 4A). To further assess the specificity
of PLD inhibitors to block the mTOR pathway, we performed
the “alcohol trap” assay. This alternative method of inhibiting
PLD activity takes advantage of the fact, that PLD preferentially
utilizes primary alcohols (1-BtOH) in the transphosphatidylation
reaction, producing phosphatidyl alcohols instead of PA;
whereas tertiary alcohols (tert-BtOH) is not a substrate for PLD
and is therefore used as a negative control [27]. As shown in
Figure 4B, 1% 1-BtOH suppressed the phosphorylation T421/
S424-S6K and S473-Akt, whereas 1% tert-BtOH had no effect
on the phosphorylation status, indicating that the observed,
effects of PLD 1 and 2 inhibitors on the mTOR pathway were
due to the suppression of PA production by PLD. As a second
alternative method to block PLD activity, we used honokiol,
Figure 2.  PLD inhibitors impair cell growth and block PLD
activity in PKD cells.  Effect of PLD1-/2-inhibitors on (A) the
cell viability, (B) DNA synthesis ability and (C) cell proliferation
were determined by MTS, BrdU and cell counting, respectively.
All types of cells were exposed to various concentrations of
either PLD1 or PLD2 inhibitor for 48 h. An experiment which is
representative of three independent experiments is shown.
doi: 10.1371/journal.pone.0073173.g002
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considered as PLD1 and PLD2 inhibitor, to treat PKD cells.
Figure 4B and Figure S1 shows, that also honokiol suppressed
the phosphorylation of S6K and Akt in human ADPKD and
OX161 cells. Taken together, our studies indicate that PLD 1
and PLD 2 inhibitors suppress mTOR signaling in PKD cells by
decreasing specifically PLD activity.
To study the functional relevance of the inhibitory effect of
PLD inhibitors on PLD activity, we examined the effect of
bypassing the need for PLD activity on both mTOR signaling
and cellular proliferation by adding exogenous PA to the cell
culture medium. Because exogenous PA has a short half-life,
we analyzed three short time points (20 min, 40 min and 60
min) of treatment with PA in both ADPKD and OX161 cells. We
found that exogenous PA (100 µM) was able to stimulate by
itself the activation of mTOR (S2448), S6K (T421/S424), Akt
(S473 and T308) (Figure 4C) without affecting PLD activity
(Figure 4D). Importantly, exogenous PA increased DNA
synthesis in human PKD cells, and rescued the inhibitory effect
of PLD inhibitors in a time-dependent manner (Figure 4E).
These results suggest that the mechanism of action of PLD
inhibitors on cellular proliferation is via inhibition of PLD-
dependent PA production and is partly mediated through an
inhibition of the mTOR signaling pathway.
PLD inhibitor triggers autophagosome formation
mTOR is a master regulator of cell proliferation and
modulates apoptosis and autophagy in many types of cells [4]
Figure 3.  PLD inhibitors block the PLD/PA pathway.  (A)
Western blots analyzing the expression of phospho-PLD1,
PLD1, phospho-PLD2, PLD2 and GAPDH either upon
treatment with different concentrations of PLD1-/2- inhibitor (for
PLD1 inhibitor: 5, 10, 15 µM, for PLD2 inhibitor: 10, 20, 30 µM)
treatment for 48 h or without treatment. (B) PLD enzyme
activity assay determining PLD activity upon treatment with
either 10 µM PLD1 inhibitor or 20 µM PLD2 inhibitor for 48 h.
An experiment which is representative of three independent
experiments is shown. Data are expressed as mean ± SD and
were analyzed by one-way ANOVA. ***p < 0.001.
doi: 10.1371/journal.pone.0073173.g003
[15]. To test whether PLD inhibitors affect downstream targets
of mTOR, we examined the apoptosis and autophagy
pathways after treatment with either PLD inhibitors, 1-BtOH,
tert-BtOH or honokiol in ADPKD and OX161 cells. As shown in
Figure 5A, cleaved caspase-3, a marker of the apoptotic
pathway, did not show an increased expression upon
treatment. But immunoblotting analysis showed a drastic
Figure 4.  PLD inhibitors block mTOR signaling pathway
and exogenous PA abrogates the effect of PLD inhibitors
on mTOR signaling and proliferation of PKD cells.  (A) PLD
inhibitors affect mTOR signaling in a dose-dependent way.
Western blots analyzing the expression of phospho-Akt, Akt,
phospho-S6K, S6K, phospho-S6, S6, phospho-4EBP1, 4EBP1
and GAPDH either upon treatment with the indicated
concentration of PLD1-/2- inhibitor for 48 h or without
treatment. (B) PKD cells were plated for 24 h and then shifted
to medium containing 0.5% serum. 1% 1-BtOH or 1% tert-
BtOH was added for 2 h, 20 µM honokiol was added for 20 h.
Western blots analyzing the expression of phospho-S6K, S6K,
phospho-Akt and Akt. (C, D) Exogenous PA stimulated mTOR
signaling in a time-dependent way, but not PLD activity. Human
PKD cells were cultured under either normal culture medium
(5% FBS) or starvation culture medium (0.5% FBS). After 24 h
starvation, cells were treated with 100 µM PA for 20, 40 and 60
minutes. Whole cell lysates were analyzed by (C) western blots
to detect the expression of phospho-mTOR, mTOR, phospho-
S6K, S6K, phospho-Akt, Akt and GAPDH. (C) Whole cell
lysates were determined by Amplex Red PLD kit to measure
the PLD activity. (E) Exogenous PA impairs the effect of PLD
inhibitors on cell growth. Cells were pretreated with either 10
µM PLD1 inhibitor or 20 µM PLD2 inhibitor for 48 h, and then
with 100 µM PA for the indicated time. DNA synthesis was
measured by using the BrdU assay. An experiment which is
representative of three independent experiments is shown.
Data are expressed as mean ± SD and were analyzed by one-
way ANOVA. * p< 0.05, ** p< 0.01.
doi: 10.1371/journal.pone.0073173.g004
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conversion of non-autophagic soluble LC3 (LC3-I) to
autophagic LC3 (LC3-II) in response to PLD1- and PLD2-
specific inhibitor and honokiol treatment in a time- and dose-
dependent manner (Figure 5A). One pathognomonic feature of
autophagy is the ultrastructural evidence of autophagosomes.
We examined PLD inhibitor-treated ADPKD and OX161 cells
using transmission electron microscopy to visualize the
induction of autophagy. Figure 5B shows that after 48 h
exposure to 10 µM PLD1- and 20 µM PLD2-inhibitors
autophagosomes were abundantly present. To further examine
the formation of autophagic vesicles, we performed
immunofluorescence analysis for LC3. As expected, LC3
aggregated substantially in response to PLD inhibitors in both
ADPKD and OX161 cells (Figure 5C).
Combinations of mTOR and PLD inhibitors have a
synergistic effect on blocking the mTOR pathway in
PKD cells
The therapeutic targeting of mTOR in PKD has attracted
attention in recent years due to a link between mTOR and
survival signals in human PKD [28–30]. However, clinical trials
with rapamycin and rapamycin analogues have been
disappointing [31,32]. We hypothesized that the lack of efficacy
could be due to elevated PLD activity that may had conferred
resistance to rapamycin [33]. To examine whether blocking
PLD activity leads to a decrease in the cellular resistance to
rapamycin, we treated ADPKD and OX161 cells with a
combination of low dose rapamycin and PLD inhibitors. The
combinatorial treatment of rapamycin and PLD inhibitors
exhibited more efficacy in blocking the phosphorylation of the
S6 protein compared with PLD inhibitors treatment alone in
ADPKD cells, but not in OX161 cells (Figure 6A). Furthermore,
we investigated whether the combination treatment had a
synergistic effect in inhibiting PKD cell proliferation. As shown
in Figure 6B, neither 5 µM PLD1- nor 10 µM PLD2-inhibitor
alone had a marked effect on cell proliferation. However, the
combination treatment of 0.1 nM rapamycin with PLD1- or
PLD2-inhibitors inhibited cell proliferation in both ADPKD and
OX161 cells.
mTOR has been shown to negatively regulate autophagy
upon nutrient limitation, which leads to suppressed mTOR
pathway activity in many cell types. Therefore, we examined
whether combining mTOR and PLD inhibitors had a synergistic
effect on inducing autophagy. A Western blot analysis showed
that LC-II conversion did not increase in response to the
combination treatment compared with single agent treatment
(Figure 6A). We further assessed whether the low dose of
rapamycin (0.1 nM) was not sufficient to induce autophagy in
PKD cells. To this aim, we treated ADPKD and OX161 cells
with a range of rapamycin concentrations for 24 h.
Interestingly; even the highest concentration of rapamycin did
not trigger autophagosome formation in PKD cells (Figure 6C).
However, the phosphorylation of the ribosomal S6 protein was
completely blocked by the rapamycin treatment under these
conditions (Figure 6C) indicating successful blockage of the
mTOR signaling pathway. Our results suggest that PKD cells
are resistant to rapamycin-induced autophagy. Taken together,
these results show that PLD inhibitors can reduce the
Figure 5.  PLD inhibitors trigger autophagosome
formation.  (A) PLD inhibitors induced autophagy in a time-
dependent way. Left panel: PKD cells were treated by either 10
µM PLD1 inhibitor or 20 µM PLD2 inhibitor for 24 h and 48 h.
Right panel: PKD cells were plated for 24 h and then shifted to
medium containing 0.5% serum. 1% 1-BtOH or 1% tert-BtOH
was added for 2 h, 20 µM honokiol was added for 20 h.
Western blots analyzing the expression of caspase-3, LC3B
and GAPDH. (B) Transmission electron microscopy analysis of
PLD1 and PLD2 inhibitor-treated HAK and OX161 cells (10 µM
and 20 µM respectively, 48 h) showing intensive vacuolization
and autophagosome-like vesicles. The lower panels show the
magnification of the black frame area in the upper panels for
each type of cell. The scale bar in the upper and lower panels
represents 10 µm and 5 µm respectively. (C)
Immunofluorescence microscopy analyzing autophagosome
distribution after PLD1-/2- inhibitor (10 µM and 20 µM)
treatment for 48 h. Cells were stained with anti-LC3B antibody.
Scale bar represents 20 µm. Representative of three
independent experiments.
doi: 10.1371/journal.pone.0073173.g005
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resistance of PKD cells to rapamycin. Furthermore,
combinations of mTOR and PLD inhibitors have a synergistic
effect in reducing cell proliferation and mTOR pathway
activation in PKD cells.
Discussion
PKD1/PKD2 gene mutations causes aberrant signaling
through the PC1-tuberin-mTOR complex leading to: 1)
deregulated tuberin-mediated nutrient signaling [34]; 2) the
vasopressin receptor 2-mediated accumulation of cyclic
adenosine monophosphate (cAMP) [35]; and 3) abnormal
Figure 6.  A combination of mTOR and PLD inhibitors has
a synergistic effect on the mTOR pathway.  (A) Combined
mTOR and PLD1-/2-inhibitor treatment has a synergistic effect
on blocking mTOR signaling in PKD cells. Western blots
analyzing the expression of phospho-S6K, S6K, LC3B and
GAPDH upon treatment with or without the indicated
concentrations of PLD1-/2-inhibitor combined with 0.1 nM
rapamycin for 48 h in PKD cells. (B) Combination treatment of
mTOR and PLD inhibitors has a synergistic effect on blocking
cell proliferation in PKD cell. BrdU assay determining DNA
synthesis in human PKD cells upon treatment with or without
the indicated concentration of PLD1-/2-inhibitor combined with
0.1 nM rapamycin for 48 h. (C) PKD cells display resistance to
rapamycin-induced autophagy. Western blots analyzing the
expression of Atg5, LC3B, phospho-S6 and GAPDH upon
treatment with or without various concentration of rapamycin
(1, 2, 3 µM) for 24 h under starvation conditions (culture
medium containing 0.5% FBS). An experiment which is
representative of three independent experiments is shown.
Data are expressed as mean ± SD and were analyzed by one-
way ANOVA. * p< 0.05, ** p< 0.01, *** p< 0.001.
doi: 10.1371/journal.pone.0073173.g006
activation of other pro-proliferative signaling pathways including
Ras/Raf/ERK, cyclin-depedent kinases (Cdks), and JAK/STAT
[36]. While there is a considerable amount of data supporting
the hypothesis that the mTOR signaling pathway plays an
important role in PKD, relatively little is known about the impact
of PLD signaling on PKD [3,37]. Here we show for the first time
that elevated PLD activity partly modulates the mTOR signaling
pathway in PKD cells suggesting a biological role for PLD/PA in
PKD progression.
In our study, we found mildly but significant elevated PLD
activity in PKD cells compare with control cells. Blockade of
PLD activity by either specific PLD inhibitors, honokiol or
“alcohol trap” treatment lead to a reduction of PA levels and
mTOR activity (Figures 2 and 4, Figure S1) and in turn,
profoundly decreased cell viability and proliferation and
increased autophagosome formation. Firstly, PA is required for
the association of mTORC1 with Raptor and mTORC2 with
Rictor. PA activates mTOR complexes by interacting with the
FKBP12-rapamycin binding (FRB) domain, the target of the
mTOR inhibitor rapamycin [11]. Secondly, PA was found to
specifically bind to and activate S6K, the downstream effector
of mTORC1 by increasing phosphorylation in T389 and T421/
S424 as well as S6K natural substrate protein S6 in 235/236
[38]. Furthermore, other proteins that are recruited or activated
by the PLD product PA, for example PI4P5 kinase, PDK, Raf,
Rac1 indicate that PLD/PA modulates survival signaling by
mTOR but also by mTOR-independent signaling pathways [39].
To further elucidate the function of PLD/PA associated
modulation of the mTOR pathway, we increased PA levels by
adding exogenous PA to stimulate mTOR signaling.
Phosphorylation of mTOR, p70S6K and Akt increased in a
time-dependent manner, suggesting that PA activates both
mTORC1 and mTORC2 pathways at multiple levels. Of note,
exogenous PA reversed the anti-proliferative effect of PLD
inhibitors, indicating that the effects of PLD inhibitors were
governed not exclusively via mTOR signaling. These
observations suggest that PLD/PA play an important role in
modulating mTOR signaling pathway in PKD.
PLD activity in mammalian cells is mediated by two different
isoforms, PLD1 and PLD2, which exhibit different regulation
and subcellular locations [40,41]. The relative contribution of
the two isoforms in mTOR pathway is not entirely clear but it
appears that depending on the particular system, either PLD
isoform can sustain mTOR pathway activation. In the present
study, we used isoform-selective PLD inhibitors which have
been reported to inhibit the respective isoforms with > 100-fold
selectivity both in in vitro assays and in cells [26]. We
confirmed the PLD isoform specific blockage of our applied
inhibitors in human PKD cells. We observed that in PKD cells,
mTOR activation was more sensitive to PLD1 than to PLD2
inhibition. The PLD1 inhibitor reduced more efficiently cell
proliferation than the PLD2 inhibitor, which correlated with the
sensitivity of the mTOR pathway activation to PLD isoform
inhibition. The results have to be interpreted in the context that
the dose-dependent effects of the PLD inhibitors only provide
limited information regarding the role of these PLD isoforms in
the mTOR pathway. It will therefore be important to investigate
the subcellular localization of PLD isoforms and mTOR in PKD,
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as well as the effects of modulating the expression of different
PLD isoforms on mTOR signaling in PKD cells in future
studies. It should be noted that PLD inhibitors had anti-
proliferative effects on both PKD and normal renal tubular
epithelial cells.
Autophagy describes the process by which cytoplasmic
materials including damaged or aged organelles and long-lived
proteins reach the lysosomes for degradation and recycling by
lysosomes [15]. Autophagy plays an important role in various
aspects of cell physiology, especially cell survival during
nutrient or energy limitation. However, autophagy can also
trigger cell death and impair cellular functions in other contexts,
underscoring its nature as a double-edged sword that can be
either protective or injurious depending on the cellular
environment, the nature and intensity of the stimulus, and the
levels of autophagy [16,42]. There is so far only one published
study reporting increased LC3-II conversion in homozygous
Han: SPRD rat kidneys (Cy/Cy) at an advanced stage of PKD,
indicating autophagy deregulation in PKD [18]. Aberrant
signaling through the mTOR pathway is a common feature of
PKD and there is a crosstalk between mTOR and autophagy in
many types of cells [17,43]. In our study, mTOR inhibitors did
not induce autophagy in PKD cells, even at high
concentrations, suggesting that PKD cells are resistant to
rapamycin-induced autophagy. Interestingly, we found that
PLD inhibitors and honokiol treated PKD cells displayed
autophagy suggesting that PLD-induced-autophagy bypassed
the mTOR signaling pathway. In line with our findings, Takita T
et al. reported that diacylglycerol kinase inhibitor reduced PA
level induced autophagy in neuronal cells [44], whereas, Dall’
Armi et al. reported that PLD1 modulated autophagy via
association with the endosomal system, partially re-localizing to
the outer membrane of autophagosome-like structures [45].
Thus, PLD modulates autophagy in different manners,
depending on cell type and subcellular localization: On one
hand, PLD/PA interact with mTOR, PI3K-Ras/ERK signaling
pathways, both regulate negatively autophagy. On the other
hand, PLD1 has been shown to foster autophagy by co-
localized with LC3 during starvation. Such a dual role has been
previously described for Vps34, a lipid enzyme that is required
for autophagy, yet also stimulates mTOR [46,47].
Rapamycin-based therapeutics effectively decreased cyst
growth and preserved renal function in a variety of animal
models for PKD [28,29,48]. However, conflicting results were
obtained in clinical trials. Two clinical trials did not show a
beneficial effect in ADPKD patients, both in early and more
progressive disease stages [31,32]. One of the possible factors
confounding the interpretation of these results could be the
dose of mTOR inhibitors used. The levels of rapamycin
tolerated in humans are lower than in mice [28]. Based on our
results, elevated activation of PLD may mitigate the effect of
rapamycin on human PKD cells. Indeed, combining mTOR and
PLD inhibitors enhanced the rapamycin-sensitivity of PKD
cells. Therefore, combination therapies that include rapamycin
and strategies that suppress PLD activity could be used to
target mTOR signaling in PKD.
In summary, our data shows that elevated PLD activity in
PKD cells. mTOR signaling pathway was partly modulated in a
PLD/PA-dependent way (Figure 7). Targeting PLD blocked cell
proliferation, decreased mTOR signaling and induced
autophagy formation. Combination of mTOR and PLD inhibitors
has a synergistic effect on retarding cell proliferation and
blocking mTOR pathway. Targeting PLD may provide a new
potential therapeutic approach for PKD.
Supporting Information
Figure S1.  Honokiol impaired cell growth and blocked
mTOR signaling in Cy/+ cells. Effect of honokiol on (A) cell
viability and DNA synthesis determined by MTS and BrdU. 48 h
after treatment initiation. (B) Honokiol affected PLD/PA and
mTOR signaling in a dose-dependent way. Western blots
analyzing the expression of phospho-PLD1, PLD1, phospho-
PLD2, PLD2, phospho-Akt, Akt, phospho-S6K, S6K, phospho-
S6 and S6 either upon treatment with the indicated
concentration of PLD1-/2- inhibitor for 48 h or without
treatment. Blots are representative of three independent
experiments. Data are expressed as mean ± SD and were
analyzed by one-way ANOVA. * p< 0.05, ** p< 0.01.
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